- Coordinator
- Ruprecht-Karls-Universitaet Heidelberg, Germany
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €4.4m
- Total cost
- —
- Partners
- 17 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101312148
What the project is doing
In the project's own words, from its summary on CORDIS.
Neuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technoloNeuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technology, the field continues to face major hurdles in early detection, risk-adapted surgery, accurate tumour classification, and the development of effective personalized treatments, underscoring the urgent need for innovative solutions to improve patient outcomes.
Current advancements in computer science, particularly in artificial intelligence (AI), are revolutionizing medicine and offer unprecedented opportunities to improve areas that have historically seen limited progress, such as neuro-oncological care. However, critical gaps remain between technical innovations and their clinical application. Moreover, physicians often lack the technical background to fully utilize AI, while computer science developments may not always address clinical realities.
The FutureMIND Doctoral Network aims to bridge these divides and fill in the gap of holistic experts needed to advance AI-driven diagnostics and discovery in neuro-oncology. FutureMIND brings together leading researchers, clinicians and entrepreneurs from eight countries to train 14 Doctoral Candidates (DCs) across different disciplines and sectors. By the end of FutureMIND, the DCs will be equipped to advance digital medicine as a new clinical tool to tackle brain cancers, with foreseeable impact on thousands of patients.
Importantly, FutureMIND will prepare a new generation of European experts capable of addressing future challenges and of preparing the EU to sovereignly lead the digital transformation in neuro-oncology, paradigmatically for other areas of medical care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Coordinator |
| Brainlab Se | Munchen | Germany | Associatedpartner |
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Participant |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Erlangen | Germany | Participant |
| Heidelberg Epignostix GmbH | Heidelberg | Germany | Associatedpartner |
| Johner Institut GmbH | Konstanz | Germany | Associatedpartner |
| Cercare Medical Aps | Aarhus C | Denmark | Associatedpartner |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii | Madrid | Spain | Participant |
| Universidad Autonoma De Madrid | Madrid | Spain | Associatedpartner |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Universitetet I Oslo | Oslo | Norway | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Oxford Nanopore Technologies Ltd | Oxford | United Kingdom | Associatedpartner |
| Proteotype Diagnostics Ltd | Cambridge | United Kingdom | Associatedpartner |
| The Queen's University of Belfast | Belfast | United Kingdom | Participant |
| The University of Nottingham | Nottingham | United Kingdom | Participant |
| Invenio Imaging Inc | Santa Clara | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI